Founded by three former Queen鈥檚 students, is growing while keeping its roots in Kingston.

The year 2022 is shaping up as one to remember for the three young entrepreneurs behind Kingston鈥檚 Spectra Plasmonics, the makers of a portable drug-testing technology that can be used by public safety organizations as well as medical clinics and safe-injection sites to test the composition of street drugs on the spot.

Spectra co-founders Malcolm, Christian and Tyler
Spectra Plasmonics co-founders Malcolm Eade, Christian Baldwin
and Tyler Whitney. Photo courtesy of Spectra Plasmonics.

In February, they received the first US patent on their technology, an important outcome following a rigorous process led by the Patent Team with Queen鈥檚 Partnerships and Innovation (QPI).

鈥淚n our space, the tech or biotech industry,鈥 says Eade, 鈥渉aving an actual granted US patent is a pretty big deal. It can influence discussions with investors in a really positive way.鈥

That鈥檚 just one of this year鈥檚 milestones for the company that he helped found along with Tyler Whitney and Christian Baldwin when they were Queen鈥檚 students in the summer program at the Dunin-Deshpande Queen's Innovation Centre back in 2017. This May, they attended a major conference in Washington D.C., on the opioid crisis in the United States, called Breaking the Stigma and Ending the Addiction Cycle. The goal was to look at alternative ways of dealing with the addiction crisis in the United States.

The American attitude to the crisis is changing, says Whitney, drawing closer to the Canadian emphasis on harm reduction rather than law enforcement. This conference drew together groups working in that world in the United States, so they could meet and learn from one another and discover how they can gain access to funding to help them.

鈥淢alcolm actually got to sit on the harm reduction panel at the conference,鈥 says Whitney. 鈥淭hat was kind of exciting, to be the Canadian voice on the panel talking about how there鈥檚 definitely new ways to combat the crisis that America hasn鈥檛 been using.鈥

鈥淚t was an ideal fit for what we鈥檙e actually currently doing,鈥 says Eade, 鈥渁nd we now have a pretty good relationship with the group that hosted the conference, which is probably the first of several over the course of the next few years. And there was really good attendance from organizations across the country which may eventually be customers or strategic partners of ours.鈥

The trip to Washington represented a pivot of sorts for the firm.

鈥淎 lot of our work now is focused on the US,鈥 says Eade. 鈥淲e鈥檙e doing a lot more business development and outreach there.鈥 In 2021, they had the opportunity, as one of four companies supported by QPI, to take part virtually in a seminar in Boston organized by the Canadian Technology Accelerator there to help firms to meet potential partners and investors in that city鈥檚 flourishing health sciences sector. 鈥淲e made some pretty good connections in Boston from that, and we actually recently reconnected with them since we鈥檙e doing a lot more US business development.鈥

Their focus is paying off. In September, their testing technology will be undergoing a month-long field trial with a potential US customer.

鈥淭hey really understood right off the bat what our solution could offer,鈥 says Eade. They can鈥檛 say much at this point, but says Eade, 鈥渟uccess with this group should lead to a lot more deployments and recognition across the US.鈥

The American emphasis isn鈥檛 surprising. As Eade points out, 鈥渢he population of Canada is just around the population of California, so there are a lot more opportunities in the US,鈥 but that doesn鈥檛 mean that they are neglecting Canada. This summer also saw three community health centres in Ontario, adopting their drug-testing technology to provide drug testing for the users of their safe injection sites.

The technology that any potential customers or partners are looking at has changed, too.

鈥淲e鈥檝e revamped the product we were piloting last year,鈥 says Malcolm. 鈥淭here鈥檚 a brand-new look to the hardware, and it performs significantly better. We鈥檝e had an increase in signal sensitivity that allows us to detect things at even lower concentrations, and there鈥檚 many more things we can detect as opposed to last year.鈥

Installing their technology in a safe injection site would allow front-line workers to analyze the drugs people are using and determine whether they were potentially fatal 鈥 a common problem with opioids bought on the street. Not only is their technology now better 鈥 it鈥檚 cheaper, too.

鈥淲e had a few specific requests from customers,鈥 says Eade. 鈥淎nd one of them was around price. We need to make the upfront costs more suited to the organizations we are selling to.鈥 Eade hopes that their revamped technology will set the 鈥減erformance standard,鈥 as he puts it, for the drug testing and harm reduction worlds.

Whatever the changes and wherever they grow, they maintain an eastern Ontario focus.

鈥淲e continue to do a lot of work with Queen鈥檚,鈥 hiring students and post-docs there and recently from St. Lawrence College as well. 鈥淥ur patent agents are still at QPI,鈥 says Eade,鈥 and we鈥檙e in QPI鈥檚 space at Seaway Co-working [in downtown Kingston] as well.鈥

The company is also working with QPI鈥檚 Advisor on Regulatory Strategies, has recently been accepted into QPI鈥檚 High-impact Mentorship program, and is receiving software development services from the Centre for Advanced Computing at Queen鈥檚. Additionally, the team continues to receive guidance and support from Launch Lab and the Southeastern Ontario Angel Network.

鈥淲e鈥檙e all Queens alumni, and still very much a Kingston and Queen鈥檚 company. We are grateful for all the support we receive from the local ecosystem,鈥 says Eade.

The programs and services referenced above are enabled with support from Queen鈥檚 and funding from the under the , which is led by the City of Kingston and includes Queen鈥檚 as a local partner, and the , led by in eastern Ontario, which includes Queen鈥檚, Launch Lab, and St. Lawrence College as regional partners. Queen鈥檚 Partnerships and Innovation offers a selection of programs and services under its HI YGK Growth Catalyst program to eligible startups and small to medium enterprises that are advancing health innovations in the Kingston region, and to technology- or science-based entrepreneurs, startups, and SMEs under its Queen's Startup Runway program and Go-to-Market Scale-Up services.